Pseudopolyrotaxanes
    53.
    发明授权
    Pseudopolyrotaxanes 失效
    假多齿轮

    公开(公告)号:US6068831A

    公开(公告)日:2000-05-30

    申请号:US214498

    申请日:1998-12-30

    摘要: The invention relates to new metal complex-containing or iodine-containing benzene derivatives that contain pseudopolyrotaxanes. They are valuable compounds for diagnosis. The pseudopolyrotaxane complexes have general formula (I), in which n represents the numbers 6, 7 or 8; m represents the numbers 2 to 50; X represents a direct bond or the radical --O--CO--CH(CH.sub.3)--; R.sub.1 and Y have the meaning that is indicated in the description and represent R.sub.3 --Y--R.sub.4 polyalkylene glycols. ##STR1##

    摘要翻译: PCT No.PCT / EP97 / 03344 Sec。 371日期1998年12月30日第 102(e)日期1998年12月30日PCT提交1997年6月25日PCT公布。 公开号WO98 / 01163 日期1998年1月15日本发明涉及含有假多齿骨架的新的含金属络合物或含碘苯衍生物。 它们是诊断有价值的化合物。 准聚轮烷配合物具有通式(I),其中n表示数6,7或8; m代表数字2到50; X表示直接键或基团-O-CO-CH(CH 3) - ; R1和Y具有说明书中所示的含义,代表R3-Y-R4聚亚烷基二醇。

    Derivatized DTPA complexes, pharmaceutical agents containing these
compounds, their use, and processes for their production
    57.
    发明授权
    Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production 失效
    衍生的DTPA复合物,含有这些化合物的药剂,其用途及其生产方法

    公开(公告)号:US5695739A

    公开(公告)日:1997-12-09

    申请号:US351126

    申请日:1994-11-30

    摘要: Compounds of a general Formula I ##STR1## wherein Z.sup.1 and Z.sup.2 in each case independently mean the residue --(CH.sub.2).sub.m --(C.sub.6 H.sub.4).sub.q --(O).sub.k --(CH.sub.2).sub.n --(C.sub.6 H.sub.4).sub.1 --(O).sub.r --R, wherein m and n means the numbers 0-20, k, l, q and r means the numbers 0 and 1, and R means a hydrogen atom, an optionally OR.sup.1 -substituted C.sub.1 -C.sub.6 -alkyl residue, or a CH.sub.2 COOR.sup.1 group with R.sup.1 meaning a hydrogen atom, a C.sub.1 -C.sub.6 -alkyl residue, or a benzyl group, X means a hydrogen atom and/or a metal ion equivalent of an element of atomic number 21-29, 42, 44 or 57-83, with the provisos that at least two the substituents X stand for a metal ion equivalent; that one of the substituents Z.sup.1 and Z.sup.2 stands for a hydrogen and the other is not H; that--if n and 1 each mean the number 0--k and r do not simultaneously mean the number 1; that --(O).sub.r --R is not --OH; and that Z.sup.1 and Z.sup.2 are not --CH.sub.2 --C.sub.6 H.sub.4 --O--CH.sub.2 --COOCH.sub.2 C.sub.6 H.sub.5 or --CH.sub.2 --C.sub.6 H.sub.4 --O--(CH.sub.2).sub.5 --COOCH.sub.2 C.sub.6 H.sub.5, as well as their salts with inorganic and/or organic bases, amino acids or amino acid amides, are valuable pharmaceutical agents, e.g., for NMR or X-ray imaging.

    摘要翻译: 其中Z 1和Z 2在每种情况下独立地表示残基 - (CH 2)m - (C 6 H 4)q - (O)k - (CH 2)n - (C 6 H 4)1 - (C 1 -C 6) O)r R,其中m和n表示数字0-20,k,l,q和r表示数字0和1,R表示氢原子,任选OR 1取代的C 1 -C 6烷基残基或 CH2COOR1基团,其中R1表示氢原子,C1-C6烷基残基或苄基,X表示原子序数21-29,42,44或57-的元素的氢原子和/或金属离子当量, 83,条件是至少两个取代基X代表金属离子当量; 取代基Z1和Z2之一代表氢,而另一个不是H; 如果n和1每个意味着数字0-k,r不同时表示数字1; - (O)r-R不是-OH; 并且Z1和Z2不是-CH2-C6H4-O-CH2-COOCH2C6H5或-CH2-C6H4-O-(CH2)5-COOCH2C6H5,以及它们与无机和/或有机碱,氨基酸或氨基酸的盐 酰胺,是有价值的药剂,例如用于NMR或X射线成像。

    PREPARATION OF HIGH-PURITY GADOBUTROL
    60.
    发明申请
    PREPARATION OF HIGH-PURITY GADOBUTROL 审中-公开
    高纯GADOBUTROL的制备

    公开(公告)号:US20140107325A1

    公开(公告)日:2014-04-17

    申请号:US14112994

    申请日:2012-04-17

    IPC分类号: C07F5/00

    摘要: What is described is a process for producing high-purity gadobutrol in a purity (according to HPLC) of more than 99.7 or 99.8 or 99.9% and the use for preparing a pharmaceutical formulation for parenteral administration. The process is carried out using specifically controlled crystallization conditions. The more recent developments in the field of the gadolinium-containing MR contrast agents (EP 0448191 B1, CA Patent 1341176, EP 0643705 B1, EP 0986548 B1, EP 0596586 B1) include the MRT contrast agent gadobutrol (Gadovist® 1.0) which has been approved for a relatively long time in Europe and more recently also in the USA under the name Gadavist®.

    摘要翻译: 所描述的是用于制备纯度(根据HPLC)高于99.7或99.8或99.9%的高纯度钆布醇的方法以及用于制备胃肠外给药的药物制剂的用途。 该方法使用特定控制的结晶条件进行。 含钆MR造影剂(EP 0448191B1,CA专利1341176,EP 0643705B1,EP0986548B1,EP0596586B1)领域中最近的发展包括已经被使用的MRT造影剂钆布醇(Gadovist?1.0) 批准在欧洲相对较长的时间,最近也在美国以Gadavist®名义批准。